Acadia Healthcare Company, Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Acadia Healthcare Company, Inc. is a leading provider of behavioral healthcare services, operating 278 facilities with approximately 12,500 beds across 40 states and Puerto Rico. The company operates through acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), and residential treatment centers.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $851.6 million | $815.6 million | $2,491.3 million | $2,379.7 million |
| Net Income (Attributable to Acadia) | $36.2 million | $68.1 million | $74.7 million | $223.0 million |
| Diluted EPS | $0.40 | $0.74 | $0.82 | $2.42 |
| Operating Cash Flow (YTD) | $218.2 million (2025) vs $13.0 million (2024) | |||
| Total Debt (Long-term + Current) | $2.31 billion (Sep 30, 2025) | |||
| Cash and Equivalents | $118.7 million (Sep 30, 2025) |
Material Changes vs. Prior Period
- Profitability Decline: Net income attributable to the company dropped 47% in Q3 2025 compared to Q3 2024 ($36.2M vs $68.1M). YTD net income decreased 66% ($74.7M vs $223.0M).
- Revenue Growth: Revenue increased 4.4% in Q3 and 4.7% YTD, driven by same-facility growth in patient days and revenue per patient day.
- Expense Increases:
- Transaction, Legal, and Other Costs: Surged to $42.9 million in Q3 2025 (vs $8.2M in Q3 2024) and $138.4 million YTD (vs $17.2M YTD 2024). This was primarily due to $38.7 million in government investigation costs in Q3 alone.
- Salaries, Wages, and Benefits: Increased 8% in Q3 to $462.2 million, reflecting wage inflation and equity-based compensation.
- Interest Expense: Increased to $36.6 million in Q3 (vs $29.9M) due to the issuance of new Senior Notes.
- Debt Refinancing: In February 2025, the company entered a new $1.65 billion Credit Facility (Term Loan + Revolver) and issued $550 million of 7.375% Senior Notes due 2033, refinancing prior obligations.
Guidance, Outlook, Risks, and Unusual Items
- Government Investigations: The company is facing significant costs related to ongoing federal and state investigations (DOJ, SEC) regarding admissions, length of stay, and billing practices. Q3 saw a spike in legal fees and settlement costs associated with these matters.
- Desert Hills Litigation: While a $400 million settlement was paid in January 2024 to resolve five cases, a sixth lawsuit was filed in late January 2024. The company states it cannot reasonably estimate the liability for this new case.
- Securities Litigation: A class action lawsuit (St. Clair County) is set for trial on November 18, 2025, unless a stay is granted. A second consolidated class action (Kachrodia) was filed in July 2025.
- Legislative Impact: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 introduces Medicaid changes, including work requirements and provider tax restrictions starting in 2026 and 2028. Management does not expect a material immediate impact due to exemptions for their patient population.
- Capital Allocation: The company repurchased $50.0 million of common stock YTD 2025 under a $300 million program. Expansion capital expenditures were $402.5 million YTD.
Investor Verification Checklist
- Legal Exposure: Verify the status and potential financial impact of the ongoing DOJ/SEC investigations and the sixth Desert Hills lawsuit, which are driving significant non-recurring costs.
- Debt Servicing: Assess the impact of the new 7.375% Senior Notes and variable-rate credit facility on future interest coverage ratios, given the current leverage ratio of 3.4x.
- Reimbursement Rates: Monitor the impact of the OBBBA legislation on Medicaid reimbursement rates and provider tax structures starting in 2026.
- Operational Efficiency: Review same-facility metrics (patient days, admissions) to confirm organic growth is offsetting the margin pressure from rising labor and legal costs.
- Cash Flow Sustainability: Confirm that operating cash flow ($218.2M YTD) remains sufficient to cover high capital expenditures ($478.6M YTD) and debt obligations without further dilution or asset sales.